| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| bevacizumab + trastuzumab | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
NA | phase 3 | unknown |
| bevacizumab + trastuzumab | farnesoid x-activated receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
NA | phase 3 | unknown |
| bevacizumab + trastuzumab | vascular endothelial growth factor a | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||